| 2023-06-07 |
Lipocine Inc. |
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 lipocine.com ↗ |
| 2022-05-12 |
Lipocine Inc. |
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results lipocine.com ↗ |
| 2022-03-01 |
Lipocine Inc. |
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH lipocine.com ↗ |
| 2022-01-05 |
Lipocine Inc. |
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference lipocine.com ↗ |
| 2021-11-04 |
Lipocine Inc. |
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH lipocine.com ↗ |
| 2021-08-25 |
Lipocine Inc. |
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study lipocine.com ↗ |
| 2021-03-04 |
Lipocine Inc. |
Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis lipocine.com ↗ |
| 2021-01-12 |
Lipocine Inc. |
Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects lipocine.com ↗ |
| 2020-12-30 |
Lipocine Inc. |
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study lipocine.com ↗ |
| 2020-11-05 |
Lipocine Inc. |
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience™ lipocine.com ↗ |
| 2020-09-21 |
Lipocine Inc. |
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study lipocine.com ↗ |
| 2020-08-03 |
Lipocine Inc. |
Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results lipocine.com ↗ |
| 2020-05-13 |
Lipocine Inc. |
Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model lipocine.com ↗ |
| 2019-10-01 |
Lipocine Inc. |
Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019 lipocine.com ↗ |
| 2019-09-30 |
Lipocine Inc. |
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144 lipocine.com ↗ |
| 2019-07-23 |
Lipocine Inc. |
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population lipocine.com ↗ |
| 2019-03-26 |
Lipocine Inc. |
Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers lipocine.com ↗ |
| 2019-03-14 |
Lipocine Inc. |
Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019 lipocine.com ↗ |
| 2019-03-12 |
Lipocine Inc. |
Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population lipocine.com ↗ |
| 2019-02-14 |
Lipocine Inc. |
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects lipocine.com ↗ |
| 2019-01-24 |
Lipocine Inc. |
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects lipocine.com ↗ |
| 2018-12-21 |
Lipocine Inc. |
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference lipocine.com ↗ |
| 2018-12-20 |
Lipocine Inc. |
Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD lipocine.com ↗ |
| 2018-11-05 |
Lipocine Inc. |
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH lipocine.com ↗ |
| 2018-10-11 |
Lipocine Inc. |
Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Late-Breaker Presentation at The Liver Meeting® 2018 lipocine.com ↗ |
|